vs
Embecta Corp.（EMBC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是Orthofix Medical Inc.的1.2倍（$261.2M vs $219.9M），Embecta Corp.净利率更高（16.9% vs -1.0%，领先17.9%），Orthofix Medical Inc.同比增速更快（2.0% vs -0.3%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $16.6M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EMBC vs OFIX — 直观对比
营收规模更大
EMBC
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出2.2%
-0.3%
净利率更高
EMBC
高出17.9%
-1.0%
自由现金流更多
OFIX
多$220.0K
$16.6M
两年增速更快
OFIX
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $219.9M |
| 净利润 | $44.1M | $-2.2M |
| 毛利率 | 61.9% | 71.1% |
| 营业利润率 | 31.9% | 0.2% |
| 净利率 | 16.9% | -1.0% |
| 营收同比 | -0.3% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.74 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCOFIX
| Q4 25 | $261.2M | $219.9M | ||
| Q3 25 | $264.0M | $205.6M | ||
| Q2 25 | $295.5M | $203.1M | ||
| Q1 25 | $259.0M | $193.6M | ||
| Q4 24 | $261.9M | $215.7M | ||
| Q3 24 | $286.1M | $196.6M | ||
| Q2 24 | $272.5M | $198.6M | ||
| Q1 24 | $287.2M | $188.6M |
净利润EMBCOFIX
| Q4 25 | $44.1M | $-2.2M | ||
| Q3 25 | $26.4M | $-22.8M | ||
| Q2 25 | $45.5M | $-14.1M | ||
| Q1 25 | $23.5M | $-53.1M | ||
| Q4 24 | $0 | $-29.1M | ||
| Q3 24 | $14.6M | $-27.4M | ||
| Q2 24 | $14.7M | $-33.4M | ||
| Q1 24 | $28.9M | $-36.0M |
毛利率EMBCOFIX
| Q4 25 | 61.9% | 71.1% | ||
| Q3 25 | 60.0% | 72.2% | ||
| Q2 25 | 66.7% | 68.7% | ||
| Q1 25 | 63.4% | 62.8% | ||
| Q4 24 | 60.0% | 69.0% | ||
| Q3 24 | 60.7% | 68.7% | ||
| Q2 24 | 69.8% | 67.8% | ||
| Q1 24 | 64.6% | 67.5% |
营业利润率EMBCOFIX
| Q4 25 | 31.9% | 0.2% | ||
| Q3 25 | 21.4% | -8.3% | ||
| Q2 25 | 31.8% | -7.9% | ||
| Q1 25 | 24.3% | -25.2% | ||
| Q4 24 | 11.0% | -5.3% | ||
| Q3 24 | 9.2% | -9.6% | ||
| Q2 24 | 20.5% | -12.5% | ||
| Q1 24 | 13.6% | -15.6% |
净利率EMBCOFIX
| Q4 25 | 16.9% | -1.0% | ||
| Q3 25 | 10.0% | -11.1% | ||
| Q2 25 | 15.4% | -6.9% | ||
| Q1 25 | 9.1% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 5.1% | -13.9% | ||
| Q2 24 | 5.4% | -16.8% | ||
| Q1 24 | 10.1% | -19.1% |
每股收益（稀释后）EMBCOFIX
| Q4 25 | $0.74 | $-0.05 | ||
| Q3 25 | $0.44 | $-0.57 | ||
| Q2 25 | $0.78 | $-0.36 | ||
| Q1 25 | $0.40 | $-1.35 | ||
| Q4 24 | $0.00 | $-0.76 | ||
| Q3 24 | $0.24 | $-0.71 | ||
| Q2 24 | $0.25 | $-0.88 | ||
| Q1 24 | $0.50 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $450.0M |
| 总资产 | $1.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCOFIX
| Q4 25 | $201.3M | $82.0M | ||
| Q3 25 | $225.5M | $62.9M | ||
| Q2 25 | $230.6M | $65.6M | ||
| Q1 25 | $209.3M | $58.0M | ||
| Q4 24 | $210.0M | $83.2M | ||
| Q3 24 | $267.5M | $30.1M | ||
| Q2 24 | $275.1M | $26.4M | ||
| Q1 24 | $299.8M | $27.0M |
总债务EMBCOFIX
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | $1.6B | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益EMBCOFIX
| Q4 25 | $-613.1M | $450.0M | ||
| Q3 25 | $-650.6M | $442.5M | ||
| Q2 25 | $-669.6M | $458.3M | ||
| Q1 25 | $-736.2M | $458.3M | ||
| Q4 24 | $-768.8M | $503.1M | ||
| Q3 24 | $-738.3M | $525.9M | ||
| Q2 24 | $-763.7M | $546.0M | ||
| Q1 24 | $-769.6M | $570.3M |
总资产EMBCOFIX
| Q4 25 | $1.1B | $850.6M | ||
| Q3 25 | $1.1B | $832.6M | ||
| Q2 25 | $1.2B | $837.2M | ||
| Q1 25 | $1.1B | $823.1M | ||
| Q4 24 | $1.1B | $893.3M | ||
| Q3 24 | $1.3B | $867.9M | ||
| Q2 24 | $1.3B | $882.0M | ||
| Q1 24 | $1.2B | $906.0M |
负债/权益比EMBCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $16.8M |
| 自由现金流率自由现金流/营收 | 6.4% | 7.6% |
| 资本支出强度资本支出/营收 | 0.2% | 4.9% |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EMBCOFIX
| Q4 25 | $17.2M | $27.7M | ||
| Q3 25 | $84.0M | $12.4M | ||
| Q2 25 | $81.2M | $11.6M | ||
| Q1 25 | $31.8M | $-18.4M | ||
| Q4 24 | $-5.3M | $23.7M | ||
| Q3 24 | $26.6M | $11.7M | ||
| Q2 24 | $-2.1M | $9.0M | ||
| Q1 24 | $24.3M | $-18.6M |
自由现金流EMBCOFIX
| Q4 25 | $16.6M | $16.8M | ||
| Q3 25 | $76.7M | $2.5M | ||
| Q2 25 | $80.8M | $4.5M | ||
| Q1 25 | $31.7M | $-25.1M | ||
| Q4 24 | $-6.8M | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $-11.8M | $-360.0K | ||
| Q1 24 | $20.9M | $-29.1M |
自由现金流率EMBCOFIX
| Q4 25 | 6.4% | 7.6% | ||
| Q3 25 | 29.1% | 1.2% | ||
| Q2 25 | 27.3% | 2.2% | ||
| Q1 25 | 12.2% | -13.0% | ||
| Q4 24 | -2.6% | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | -4.3% | -0.2% | ||
| Q1 24 | 7.3% | -15.4% |
资本支出强度EMBCOFIX
| Q4 25 | 0.2% | 4.9% | ||
| Q3 25 | 2.8% | 4.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | 0.0% | 3.5% | ||
| Q4 24 | 0.6% | 4.0% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 3.6% | 4.7% | ||
| Q1 24 | 1.2% | 5.6% |
现金转化率EMBCOFIX
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
